Neurobo Pharmaceuticals Stock Price on June 4, 2024
| NRBO Stock | USD 2.37 0.02 0.85% |
Below is the normalized historical share price chart for Neurobo Pharmaceuticals extending back to August 05, 2016. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Neurobo Pharmaceuticals stands at 2.37, as last reported on the 25th of November, with the highest price reaching 2.45 and the lowest price hitting 2.35 during the day.
If you're considering investing in Neurobo Stock, it is important to understand the factors that can impact its price. Neurobo Pharmaceuticals has Sharpe Ratio of -0.0985, which conveys that the firm had a -0.0985% return per unit of risk over the last 3 months. Neurobo Pharmaceuticals exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neurobo Pharmaceuticals' Risk Adjusted Performance of (0.08), mean deviation of 3.39, and Standard Deviation of 4.85 to check out the risk estimate we provide.
At this time, Neurobo Pharmaceuticals' Total Stockholder Equity is very stable compared to the past year. As of the 25th of November 2024, Common Stock Shares Outstanding is likely to grow to about 5.3 M, while Common Stock Total Equity is likely to drop about 17.9 K. . At this time, Neurobo Pharmaceuticals' Price Book Value Ratio is very stable compared to the past year. As of the 25th of November 2024, Price Earnings To Growth Ratio is likely to grow to 0.02, while Price Earnings Ratio is likely to drop (1.58). Neurobo Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 5th of August 2016 | 200 Day MA 3.8423 | 50 Day MA 2.7972 | Beta (0.28) |
Neurobo |
Sharpe Ratio = -0.0985
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NRBO |
Estimated Market Risk
| 4.85 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neurobo Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurobo Pharmaceuticals by adding Neurobo Pharmaceuticals to a well-diversified portfolio.
Price Book 1.5765 | Book Value 1.505 | Enterprise Value -1.1 M | Enterprise Value Ebitda (0.43) | Shares Float 2.1 M |
Neurobo Pharmaceuticals Main Headline on 4th of June 2024
Acquisition by Swirsky Douglas J of 60000 shares of Neurobo ... by Swirsky Douglas J
Filed transaction by Neurobo Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3
Neurobo Pharmaceuticals Valuation on June 4, 2024
It is possible to determine the worth of Neurobo Pharmaceuticals on a given historical date. On June 4, 2024 Neurobo was worth 4.0 at the beginning of the trading date compared to the closed value of 4.05. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Neurobo Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Neurobo Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Neurobo Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Neurobo Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 3.95 | 4.13 | 3.82 | 3.98 | 14,511 | |
06/04/2024 | 4.00 | 4.07 | 3.88 | 4.05 | 10,752 |
| 4.04 | 4.15 | 3.91 | 4.02 | 18,009 |
| Backtest Neurobo Pharmaceuticals | | | Neurobo Pharmaceuticals History | | | Neurobo Pharmaceuticals Valuation | Previous | Next |
Neurobo Pharmaceuticals Trading Date Momentum on June 4, 2024
| On June 05 2024 Neurobo Pharmaceuticals was traded for 4.02 at the closing time. The top price for the day was 4.15 and the lowest listed price was 3.91 . The trading volume for the day was 18 K. The trading history from June 5, 2024 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 0.74% . The trading delta at closing time against the current closing price is 2.72% . |
Neurobo Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Neurobo Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Neurobo Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Neurobo financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Neurobo Pharmaceuticals Stock history
Neurobo Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Neurobo is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Neurobo Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Neurobo Pharmaceuticals stock prices may prove useful in developing a viable investing in Neurobo Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 5.1 M | 5.3 M | |
| Net Loss | -13.8 M | -14.4 M |
Neurobo Pharmaceuticals Quarterly Net Working Capital |
|
Neurobo Pharmaceuticals Stock Technical Analysis
Neurobo Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Neurobo Pharmaceuticals Period Price Range
Low | November 25, 2024
| High |
0.00 | 0.00 |
Neurobo Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Neurobo Pharmaceuticals November 25, 2024 Market Strength
Market strength indicators help investors to evaluate how Neurobo Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neurobo Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Neurobo Pharmaceuticals stock market strength indicators, traders can identify Neurobo Pharmaceuticals entry and exit signals to maximize returns
Neurobo Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Neurobo Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Neurobo Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Neurobo to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.84) | |||
| Total Risk Alpha | (1.31) | |||
| Treynor Ratio | (0.23) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Return On Assets (0.74) | Return On Equity (1.61) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.